ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $401,220.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00. Following the sale, the chief executive officer directly owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Price Performance

ANIP traded down $1.09 during trading on Wednesday, reaching $74.56. The stock had a trading volume of 411,903 shares, compared to its average volume of 380,614. The stock has a market cap of $1.71 billion, a PE ratio of 16.07 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The business has a 50-day moving average of $80.05 and a 200-day moving average of $78.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. The company’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ANIP. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Guggenheim reduced their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $105.83.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Amundi boosted its stake in shares of ANI Pharmaceuticals by 595.5% during the second quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company’s stock valued at $2,632,000 after purchasing an additional 27,222 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $1,449,000. California State Teachers Retirement System raised its holdings in ANI Pharmaceuticals by 7,977.4% during the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company’s stock valued at $164,200,000 after buying an additional 1,959,017 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $724,000. Finally, Penn Capital Management Company LLC boosted its position in ANI Pharmaceuticals by 15.4% during the 2nd quarter. Penn Capital Management Company LLC now owns 207,362 shares of the specialty pharmaceutical company’s stock valued at $17,183,000 after buying an additional 27,646 shares during the period. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.